Gene therapy is effective against many diseases and even has the potential to address enduring global health challenges like HIV. However, gene therapy as it currently exists is astronomically expensive to develop and administer. What’s more, the burden of diseases that may be most susceptible to gene therapy, such as sickle cell disease and potentially HIV, is concentrated primarily in the developing world, particularly in sub-Saharan Africa.

My guest today, Dr. Boro Dropulic, is working to close that gap and bring these advanced therapies to places where they are needed most. He is the Executive Director of Caring Cross, a nonprofit dedicated to both developing advanced medical cures and making them widely accessible. In our conversation, he explains why these gene therapies are so expensive today and how to make them affordable for health systems in the developing world.